Insilico Medicine to Present Phase 1 ISM6331 Results at ESMO 2026
Insilico Medicine has announced that first-in-human Phase 1 data for ISM6331, an AI-designed pan-TEAD inhibitor, has been accepted for a ...
Insilico Medicine has announced that first-in-human Phase 1 data for ISM6331, an AI-designed pan-TEAD inhibitor, has been accepted for a ...
Cancer immunotherapy has revolutionized the landscape of blood cancer treatment, especially through the deployment of bioengineered T cells. Among these, ...
In a groundbreaking discovery that may revolutionize the future of cancer immunotherapy, researchers at the UC Davis Comprehensive Cancer Center ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine